Annovis Bio Bolsters Neurodegenerative Research with Key Biostatistics Appointment
Annovis Bio strengthens its scientific team by appointing Hui Liu as Director of Biostatistics, enhancing its capabilities in clinical trial design and data analysis for neurodegenerative disease research.
Annovis Bio Inc. has appointed Hui Liu as its new Director of Biostatistics, a strategic move that could significantly impact the company's ongoing Phase 3 Alzheimer's disease trial. Liu brings nearly two decades of extensive experience in clinical trial design, statistical analysis, and regulatory submission support across multiple therapeutic areas.
The appointment signals Annovis Bio's commitment to advancing its research in neurodegenerative disorders, particularly Alzheimer's and Parkinson's diseases. Liu's expertise is expected to reinforce the scientific integrity of the company's data and enhance its regulatory strategies for developing innovative therapies targeting neurotoxic proteins.
With over 19 years of professional experience, Liu is positioned to play a critical role in improving the company's approach to clinical trials. Her addition to the team suggests a sophisticated and data-driven strategy for developing potential treatments that could restore brain function and improve patients' quality of life.
The strategic hiring demonstrates Annovis Bio's focus on rigorous scientific methodologies and its dedication to potentially transformative research in neurodegenerative disease treatment. By strengthening its biostatistics leadership, the company aims to accelerate its progress toward developing more effective therapeutic interventions.